Identification of Methods to Predict Women's response to Breast Cancer chemotherapy

Most women who have had surgery for early stage breast cancer are offered adjuvant chemotherapy. This type of chemotherapy can reduce the chance of the cancer recurring, but this treatment causes many side effects. Many women who receive adjuvant chemotherapy will not benefit from it but do suffer its negative side effects. For this reason, there is a need to identify the women who will and will not benefit from receiving chemotherapy, thus improving breast cancer treatment and sparing women who will not respond the significant costs and potentially toxic side effects of the adjuvant chemotherapy.

Dr Maeve Hennessy is now undertaking a two-year Breakthrough Cancer Clinical Research Fellowship to identify the biological characteristics that predict a woman’s response to breast cancer therapy. Her work will contribute to the personalisation of treatment for early stage breast cancer. This will spare certain patients from unnecessary toxic therapy and also ensure that, at diagnosis, patients are put on the correct treatment pathway.

Publications

Hennessy MA, Leal JP, Huang CY, Solnes LB, Denbow R, Abramson VG, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Winer EP, Krop IE, Wolff AC, Cimino-Mathews A, Wahl RL, Stearns V, Connolly RM. Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). J Nucl Med. 2023 Nov;64(11):1690-1696. doi: 10.2967/jnumed.123.265853. Epub 2023 Aug 31. PMID: 37652539. Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial) – PubMed (nih.gov)

Maeve Hennessy was awarded the Alavi-Mandell Award in March 2024 for this publication